[1]SU CH, LIN Y, CAI L.Genetic factors, viral infection, other factors and liver cancer:an update on current progress[J].Asian Pac J Cancer Prev, 2013, 14 (9) :4953-4960.
|
[2]WEI KR, YU X, ZHENG RS, et al.Incidence and mortality of liver cancer in China[J].Chin J Cancer, 2014, 33 (8) :388-394.
|
[3]ZHAO RR, DENG YD, YUAN H, Epidemiological and clinical features of primary liver cancer:an analysis of 236 patients[J].J Clin Hepatol, 2016, 32 (8) :1538-1542. (in Chinese) 赵荣荣, 邓永东, 袁宏.236例原发性肝癌患者流行病学及临床特点分析[J].临床肝胆病杂志, 2016, 32 (8) :1538-1542.
|
[4]MORALES-ROMERO J, VARGAS G, GARCIA-ROMAN R.Occult HBV infection:a faceless enemy in liver cancer development[J].Viruses, 2014, 6 (4) :1590-1611.
|
[5]NG E, MYERS RP, MANUEL D, et al.Hospital stays for hepatitis B or C virus infection or primary liver cancer among immigrants:a census-linked population-based cohort study[J].CMAJ Open, 2016, 4 (2) :e162-e168.
|
[6]WANG L, ZOLLINGER T, ZHANG J.Association between Helicobacter pylori infection and liver cancer mortality in 67 rural Chinese counties[J].Cancer Causes Control, 2013, 24 (7) :1331-1337.
|
[7]National Healthand Family Planning Commission of the People's Republic of China.Diagnosis, management, and treatment of hepatocellularcarcinoma (V 2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.
|
[8]FU J, WANG H.Precision diagnosis and treatment of liver cancer in China[J].Cancer Lett, 2018, 412 (1) :283-288.
|
[9]TANG ZY.Discussion on the road of liver cancer prevention and treatment in China[J].Chin J Oncol, 2015, 37 (9) :641-643. (in Chinese) 汤钊猷.试论中国肝癌防治之路[J].中华肿瘤杂志, 2015, 37 (9) :641-643.
|
[10]ZHANG W, SUN B.Impact of age on the survival of patients with liver cancer:an analysis of 27 255 patients in the SEER database[J].Oncotarget, 2015, 6 (2) :633-641.
|
[11]PATEL T, DANGELL C, MAHESHWARI S.Impact of age on screening and surveillance for primary liver cancer[J].Am J Gastroenterol, 2006, 101 (4) :768-774.
|
[12]TJONA S, SINT NICOLAAS J, KWEKKEBOOM J, et al.Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine:an association with C2 monitoring and recipient age[J].Liver Transpl, 2010, 16 (7) :837-846.
|
[13]WANG M, WANG Y, FENG X, et al.Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas:experience of the Chinese National Cancer Center[J].Int J Infect Dis, 2017, 65:15-21.
|
[14]WANG X, WANG Z, WU L.Combined measurements of tumor number and size helps estimate the outcome of resection of Barcelona clinic liver cancer stage B hepatocellular carcinoma[J].BMC Surg, 2016, 16:22.
|
[15]LEE SD, LEE B, KIM SH, et al.Proposal of new expanded selection criteria using total tumor size and (18) F-fluorodeoxyglucose-positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma:the National Cancer Center Korea criteria[J].World J Transplant, 2016, 6 (2) :411-422.
|
[16] ZHANG HH, SUN SB, HAN CJ, et al.A 3-year-follow-up study on the prognosis of‘two-route chemotherapy’on liver cancer patients with portal vein tumor thrombus[J].Chin J Epidemiol, 2012, 33 (11) :1181-1183. (in Chinese) 张焕虎, 孙胜波, 韩传吉, 等.双途径化疗对合并门静脉癌栓肝癌患者预后的影响 (3年随访报告) [J].中华流行病学杂志, 2012, 33 (11) :1181-1183.
|
[17]KOELINK CJ, van HASSELT P, van der PLOEG A, et al.Tyrosinemia type I treated by NTBC:how does AFP predict liver cancer?[J].Mol Genet Metab, 2006, 89 (4) :310-315.
|
[18]LIU H, XU Y, XIANG J, et al.Targeting alpha-fetoprotein (AFP) -MHC complex with CAR T-cell therapy for liver cancer[J].Clin Cancer Res, 2017, 23 (2) :478-488.
|
[19]BENEJ M, CAPOV I, SKRICKOVA J, et al.Association of the postoperative white blood cells (WBC) count in peripheral blood after radical surgical treatment of left upper lobe non-small cell lung cancer (NSCLC) with overall survival-single center results[J].Bratisl Lek Listy, 2017, 118 (5) :299-301.
|
[20]HU G, TUOMILEHTO J, PUKKALA E, et al.Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer[J].Hepatology, 2008, 48 (1) :129-136.
|
[21]LU Y, LU Q, CHEN HL.Diagnosis of primary liver cancer using lectin affinity chromatography of serum alkaline phosphatase[J].J Exp Clin Cancer Res, 1997, 16 (1) :75-80.
|
[22]ZHAO HZ, QI QG.Biochemical markers and HBV DNA levels in hepatitis B virus-related primary liver cancer patients with HBe Ag positive and HBe Ag negative[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (4) :87-90. (in Chinese) 赵海珍, 其其格.HBe Ag阳性及HBe Ag阴性乙型肝炎病毒相关原发性肝癌患者生物化学指标及病毒载量[J/CD].中国肝脏病杂志:电子版, 2016, 8 (4) :87-90.
|
[23]RECIPON G, PIVER E, CAILLE A, et al.Is procalcitonin increased in cases of invasive amoebiasis?A retrospective, observational study[J].Diagn Microbiol Infect Dis, 2015, 83 (4) :395-399.
|
[24]DABBOUS HK, ALI-ELDIN FA, MONTASSER IM.Role of procalcitonin in diagnosis of bacterial infection in trans-arterial chemoembolisation treated hepatocellular carcinoma patients[J].Arab J Gastroenterol, 2015, 16 (1) :10-13.
|
[25]YOU H, MA H, LIU T, et al.Different models of HBe Ag seroconversion predicated by on-treatment ALT and HBV DNA profiles[J].J Viral Hepat, 2009, 16 (12) :876-882.
|